ACR Share Price Performance
AU$0.016
-0.03 (-60.98%)
82.2% undervalued intrinsic discount
AU$0.09
Fair Value
Price AU$0.016
AnalystConsensusTarget AU$0.09
Fair ValueAU$0.09
Share Pricen/a
Acrux Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
ACR Community Narratives
AN
Fair Value AU$0.09 82.2% undervalued intrinsic discount
New Product Launches Including Cone 75% Will Expand Market Presence
1users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
New Product Launches Including Cone 75% Will Expand Market Presence
Key Takeaways Expansion into niche markets and strategic licensing agreements are aimed at enhancing net margins and diversifying revenue streams. Product pipeline growth coupled with a strong financial position supports sustained long-term revenue and earnings growth.Read more
1users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
AU$0.09
82.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
173.56% p.a.
Profit Margin
44.47%
Future PE
4.32x
Price in 2028
AU$0.11
Trending Discussion
Recently Updated Narratives
AN
New Product Launches Including Cone 75% Will Expand Market Presence
Fair Value: AU$0.09 82.2% undervalued intrinsic discount
13 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Acrux Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -0.015
- -93.95%
- -499.58%
- 168.8%
About ACR
- Founded
- 1998
- Employees
- n/a
- CEO
- WebsiteView website
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
